07:00 , Jun 8, 2015 |  BioCentury  |  Finance

Xanthopoulos' passion play

With his role of running Regulus Therapeutics Inc. (NASDAQ:RGLS) in the rearview mirror, Kleanthis Xanthopoulos expects his new job at Vendel Group will be a smaller-scale, California version of what Third Rock Ventures does -...
07:00 , Oct 20, 2014 |  BioCentury  |  Product Development

Walking the toll road

Even after a series of clinical setbacks in the mid-2000s cooled investor and pharma interest in the once white-hot field of toll-like receptors, several companies continued toiling away. Now the spark may be rekindling as...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Celladon management update

Celladon Corp. (NASDAQ:CLDN), San Diego, Calif.   Business: Cardiovascular, Endocrine/Metabolic, Neurology   Hired: Elizabeth Reed as VP and general counsel, a newly created position, formerly SVP of legal affairs, general counsel and corporate secretary at...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Targeting translation

Targeting translation Effector Therapeutics Inc. recorded the second-largest series A round thus far this year, driven by novel biology and founders and management with a track record of exits. The company raised $45 million in...
07:00 , Oct 22, 2012 |  BioCentury  |  Product Development

Nuclear pacifism

Phase IIb data released by Abbott Laboratories last week provide the most compelling argument to date that all-oral HCV cocktails do not require a nucleotide-based NS5B inhibitor. An abstract released ahead of the American Association...
07:00 , Aug 6, 2012 |  BioCentury  |  Strategy

Freedom to deal Strategy

Idenix Pharmaceuticals Inc. believes it is finally positioned to become a player in the race for an all-oral HCV regimen after restructuring its nine-year old collaboration with Novartis AG . But by now several large...
07:00 , Jul 16, 2012 |  BioCentury  |  Strategy

Burying Nutley

When Roche acquired Genentech Inc. in 2009, it was clear the pharma's Nutley, N.J., facility had been underperforming for years. Three years later, the continued poor performance of the Nutley site made it an obvious...
07:00 , Jul 2, 2012 |  BioCentury  |  Strategy

Revving the engine

After 18 months on the job, EVP of R&D Douglas Williams is making good on his promise to reignite target discovery efforts at Biogen Idec Inc. , starting with several new hires, including a CSO...
07:00 , May 14, 2012 |  BC Week In Review  |  Company News

Ruga management update

Ruga Corp. , Palo Alto, Calif.   Business: Cancer   Hired: James Freddo as CMO and head of clinical development, formerly SVP of drug development and CMO at Anadys Pharmaceuticals Inc. , which Roche acquired...
08:00 , Mar 5, 2012 |  BioCentury  |  Product Development

Dynamic duo

Novartis AG 's deal with Enanta Pharmaceuticals Inc. gives the pharma two angles for targeting HCV that act directly and indirectly against the non-structural protein 5A. The combination of Enanta's direct inhibitor with the pharma's...